China allows clinical trials of new Covid-19 vaccine

Source : 112 Ukraine

It is noted that the new vaccine against Covid-19 is recombinant
17:30, 11 April 2021

Associated Press

China has authorized Sinopharm pharmaceutical company to conduct human clinical trials of the third coronavirus vaccine. This was reported by the press service of Sinopharm.

"On April 9, 2021, the new recombinant coronavirus vaccine Sinopharm of Chinese National Institute of Biological Sciences received approval for clinical trials from the National Health Products Administration," said in a statement.

The report notes that the other two vaccines were inactivated (with the virus "killed"). The new one is recombinant.

Related: Coronavirus in Ukraine dashboard: online

"The recombinant vaccine for the coronavirus is based on the natural structural characteristics of the novel receptor-binding domain (RBD) of the coronavirus spike protein (S-protein) and uses structural biology and computational biology for independent design and development," the company said.

On April 1, the World Health Organization recognized the effectiveness of the coronavirus vaccine from the Chinese pharmaceutical companies Sinopharm and Sinovac. The organization said that these drugs meet the requirements of the WHO.

According to preliminary data from clinical trials conducted in different countries, the effectiveness of the Sinopharm vaccine is approximately 79.34%, while the effectiveness of Sinovac ranges from 50.65 to 83.5%.

Related: Ukraine, Turkey share common vision of security threats in Black Sea region, - Zelensky

Система Orphus

If you find an error, highlight the desired text and press Ctrl + Enter, to tell about it

see more